On Thursday, Shares of Baxter International Inc. (NYSE:BAX), gained 1.42% to $37.02.
Baxter International, will host a quarterly conference call to talk about its second quarter 2015 financial results on Wednesday, July 29, 2015, at 4:00 p.m. Central Time.
To access the call, dial 844.471.1702 (dom) or 225.239.4663 (int’l). Please dial into the call at least ten minutes preceding to the start of the call for the operator to connect you. The Conference ID is 74585626.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Shares of Eli Lilly and Company (NYSE:LLY), inclined 0.26% to $87.48, during its last trading session.
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met recently to talk about the data supporting Eli Lilly and Company, necitumumab in combination with gemcitabine and cisplatin for use in first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC).
Squamous NSCLC is a devastating and difficult-to-treat form of lung cancer. The five-year survival rate for patients with metastatic disease is less than five percent.[1] Necitumumab in combination with gemcitabine and cisplatin is the first regimen to show a noteworthy improvement in overall survival over chemotherapy alone, specifically in the first-line setting.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
Finally, Orange (NYSE:ORAN), ended its last trade with 1.16% gain, and closed at $14.82.
Orange Business Services declared that it has reached an agreement with Tata Communications to expand its network footprint in India. The Network-to-Network Interconnect (NNI) agreement is part of a planned partnership between the two companies and will enhance Orange domestic coverage ten-fold to over 120 cities to meet customer demand.
The NNI will enable Orange to utilize Tata Communications’ 120 points of presence (PoPs), extending Orange Business Services’ reach to tier-two and tier-three cities such as Bhopal, Kanpur and Visakhapatnam. The raised domestic footprint of the Orange network in India is particularly suited to support the expansion plans of global multinational customers looking to connect to the farthest corners of India with robust and reliable network services, featuring global service level agreements (SLA) and straightforward billing.
It also comprises access to Orange Business VPN – a fully secured and managed network solution that allows data, voice and video to run on the same IP-based MPLS network – from all locations covered by this network agreement.
Orange provides a range of fixed telephony and mobile telecommunications, data transmission, and other value-added services to consumers, businesses, and other telecommunications operators worldwide. The company offers mobile, fixed-line, and carrier services; sells mobile devices and accessories; and sells and rents fixed-line equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
